Entera Bio (ENTX) Depreciation & Amortization (CF) (2021 - 2026)

Entera Bio (ENTX) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $7000.0 the latest figure, recorded in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 12.5% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29000.0 (down 29.27% YoY) and the FY2025 annual result came in at $30000.0, down 34.78% from the prior year.
• Depreciation & Amortization (CF) steadied at $7000.0 in Q1 2026 per ENTX's latest filing, from $7000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for ENTX reached as high as $16000.0 in Q1 2022 and fell as low as $7000.0 in Q2 2025.
• A 5-year average of $11941.2 and a median of $13000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 77.78% — and 2025, when it sank 38.46%.
• Year by year, Depreciation & Amortization (CF) stood at $16000.0 in 2022, then slipped by 18.75% to $13000.0 in 2023, then declined by 15.38% to $11000.0 in 2024, then slumped by 36.36% to $7000.0 in 2025, then changed by 0.0% to $7000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $7000.0, $7000.0, and $8000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.